Long-term prevention of recurrent DVT/PE
| Standard dose | Comments/dose adjustment | |
|---|---|---|
| Apixaban503 | 2.5 mg BID | |
| Dabigatran504 | 150 mg BID | No pre-specified dose-reduction criteria in clinical triala |
| Edoxaban473,500,505 | 60 mg QDb | |
| Rivaroxaban506 | 10 mg QD | c |
BID, twice daily; QD, once daily.
a
SmPC: 110 mg BID if age ≥80 years, concomitant verapamil (both based on pharmacokinetics/pharmacodynamics analyses; not studied in this setting).
b
Not specifically studied, follow-up data available up to 12 months in phase III trial.
c
SmPc: 20 mg QD in patients at high risk of recurrence.